Edgewise Therapeutics, Inc. (EWTX) — Financial statements
Income statement, balance sheet, and cash flow for Edgewise Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 151↑19.2% | 127↑39.7% | 91↑68.2% | 54↑67.9% | 32 | |
| General & Administrative Expenses | 40↑25.6% | 32↑35.9% | 23↑33.1% | 18↑59.9% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 40↑25.6% | 32↑35.9% | 23↑33.1% | 18↑59.9% | 11 | |
| Other Expenses | -2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 189↑19.1% | 159↑38.9% | 114↑59.6% | 72↑65.8% | 43 | |
| Total Costs & Expenses | 191↑20.5% | 159↑38.9% | 114↑59.6% | 72↑65.8% | 43 | |
| Operating Results | ||||||
| Operating Income | -191↓20.5% | -159↓38.9% | -114↓59.6% | -72↓65.8% | -43 | |
| Depreciation & Amortization | 2↓1.0% | 2↑32.2% | 2↑221.9% | 0.54↑97.8% | 0.27 | |
| EBITDA | -166↓5.7% | -157↓39.0% | -113↓58.4% | -71↓65.6% | -43 | |
| EBIT | -168↓5.6% | -159↓38.9% | -114↓59.6% | -72↓65.8% | -43 | |
| Interest & Other Income | ||||||
| Net Interest Income | 24↓5.6% | 25↑76.3% | 14↑1148.3% | -1↓436.8% | 0.40 | |
| Interest Income | 24↓5.6% | 25↑76.3% | 14↑432.8% | 3↑562.7% | 0.40 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 4 | 0.00 | |
| Non-Operating Income | -24 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 24↓5.6% | 25↑76.3% | 14↑253.3% | 4↑899.5% | 0.40 | |
| Income Before Tax | -168↓25.4% | -134↓33.6% | -100↓48.1% | -68↓58.0% | -43 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -168↓25.4% | -134↓33.6% | -100↓48.1% | -68↓58.0% | -43 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -168↓25.4% | -134↓33.6% | -100↓48.1% | -68↓58.0% | -43 | |
| Bottom-Line Net Income | -168↓25.4% | -134↓33.6% | -100↓48.1% | -68↓58.0% | -43 | |
| EPS (Basic) | -1.63↓12.4% | -1.45↑7.6% | -1.57↓24.6% | -1.26↓46.5% | -0.86 | |
| EPS (Diluted) | -1.63↓12.4% | -1.45↑7.6% | -1.57↓24.6% | -1.26↓46.5% | -0.86 | |
| Weighted Average Shares | 103↑11.4% | 92↑45.0% | 64↑18.9% | 54↑8.3% | 50 | |
| Weighted Average Diluted Shares | 103↑11.4% | 92↑45.0% | 64↑18.9% | 54↑8.3% | 50 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.